Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

How Intract Is Helping Shape Microbiome-Based Therapies

Executive Summary

Bill Lindsay, CEO of University College London spin-out Intract Pharma, tells Scrip in an interview how the firm’s novel technologies are expected to play a key role in the effective delivery of microbiome-based therapies.
Advertisement

Related Content

Scrip Asks...What Is The Current Trend For Open Innovation In Asia?
BiomX Wants To Reverse The Focus Of Microbiome Therapy
Microbiome Clinical Studies Loom Large In 2018

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100641

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel